Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Abstract

Background and aims :Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora.Studies have also indicated that the occurance of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora.Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora. Results Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. All these changes were statistically significant (p < 0.05). Conclusion One-year metformin therapy for FAP is safe and effective, and maybe mediated by modulating the intestinal flora. This study provides new ideas and strategies for the prevention of adenomatous polyp carcinogenesis in FAP and possible mechanisms of preventive action.